Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection
- Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. Nahon, Pierre; Sutton, Angela; Rufat, Pierre; Simon, Chantal; Trinchet, Jean-Claude; Gattegno, Liliane; Beaugrand, Michel; Charnaux, Nathalie; Rodrigo, Luis; Shimada, Mitsuo; Einarsson, Curt // World Journal of Gastroenterology;2/7/2008, Vol. 14 Issue 5, p713
AIM: To explore the influence of polymorphisms in genes encoding for the chemokines Stromal cell-Derived Factor-1 (SDF-1)/CXCL12 and Monocyte Chemotactic Protein-1 (MCP-1) /CCL2, or for the chemokine receptor CCR5 on the risks of liver-related death and hepatocellular carcinoma (HCC) occurrence...
- Association of TIMP- 1 and TIMP- 2 Gene Polymorphisms with Progression of Liver Fibrosis in Patients with Type C Chronic Liver Disease. Ikebuchi, Yuichiro; Ishida, Chihiro; Okamoto, Kinya; Murawaki, Yoshikazu // Biochemical Genetics;Aug2013, Vol. 51 Issue 7/8, p564
We examined the association of TIMP- 1 and TIMP- 2 gene polymorphisms with the progression of chronic liver disease related to the hepatitis C virus (HCV). We used PCR to analyze 188 patients with HCV-related liver disease (95 with chronic hepatitis and 93 with cirrhosis) for TIMP- 1 372 T/C and...
- Polimorfismos GenÃ©ticos da IL28B e a TerapÃªutica da Hepatite C. Ramalho, F. // RPDI - Revista Portuguesa de DoenÃ§as Infecciosas;mai-ago2012, Vol. 8 Issue 2, p94
Hepatitis C virus infection (HCV) is estimated to affect 170 million people worldwide. This infection results in 20-30% of the cases with progressive chronic hepatitis to liver cirrhosis and Hepatocelular carcinoma. Currently the most effective viral therapy for viral clearance is the...
- Influence of Genetic Polymorphisms of Tumor Necrosis Factor Alpha and Interleukin 10 Genes on the Risk of Liver Cirrhosis in HIV-HCV Coinfected Patients. Corchado, Sara; Márquez, Mercedes; Montes de Oca, Montserrat; Romero-Cores, Paula; Fernández-Gutiérrez, Clotilde; Girón-González, José-Antonio // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1
Objective: Analysis of the contribution of genetic (single nucleotide polymorphisms (SNP) at position -238 and -308 of the tumor necrosis factor alpha (TNF-Î±) and -592 of the interleukin-10 (IL-10) promotor genes) and of classical factors (age, alcohol, immunodepression, antirretroviral...
- Retraction. // Acta Medica Marisiensis;Jun2014, Vol. 60 Issue 3, p134
A correction to the article "Relationship Between Genotypes of Hepatitis C Virus and the Progression to Cirrhosis in Chronic Hepatitis C Patients" that was published in the 2014 issue is presented.
- Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. Arao, Motohiro; Murase, Kenichi; Kusakabe, Atsuhiko; Yoshioka, Kentaro; Fukuzawa, Yoshitaka; Ishikawa, Tetsuya; Tagaya, Tsuneaki; Yamanouchi, Kunio; Ichimiya, Hiroshi; Sameshima, Yoichi; Kakumu, Shinichi // Journal of Gastroenterology;2003, Vol. 38 Issue 4, p355
Background. To examine the relationship between hepatitis C virus (HCV) infection and diabetes mellitus (DM) in Japanese populations, a retrospective study was done in 866 patients with chronic viral disease. Methods. The present study included 707 HCV-infected and 159 hepatitis B virus...
- Sofosbuvir-based regimens good value for HCV genotype 2/3. // PharmacoEconomics & Outcomes News;Apr2015, Vol. 725 Issue 1, p29
The article talks about Sofosbuvir-based regimens which provides a good value for patients with treatment experience of hepatitis C virus (HCV) genotypes with or without cirrhosis, but for HCV patients without treatment experience & cirrhosis it crosses the willingness-to-pay(WTP) threshold in U.S.
- Successful treatment of post-transplant hepatitis C virus cirrhosis with daclatasvir and asunaprevir. Ozaras, Resat; Mete, Bilgul; Yemisen, Mucahit; Inanc Balkan, Ilker; Alkan, Mustafa; Tabak, Fehmi // Journal of Gastrointestinal & Liver Diseases;Sep2015, Vol. 24 Issue 3, p393
The article demonstrates the successful treatment of post-transplant hepatitis C virus (HCV) cirrhosis with daclatasvir and asunaprevir in a 55-year-old woman presented with HCV infection detected during screening.
- Improving treatment not enough to reduce liver disease burden. Schlansky, Barry // Clinician Reviews;Nov2015, Vol. 25 Issue 11, p49
The article discusses findings of a study which forecasted decline in the prevalence of cirrhosis in 2021 and continued surge in hepatitis C virus (HCV).
- Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis. Tanabe, Kenneth K.; Lemoine, Antoinette; Finkelstein, Dianne M.; Kawasaki, Hiroshi; Fujii, Tsutomu; Chung, Raymond T.; Lauwers, Gregory Y.; Kulu, Yakup; Muzikansky, Alona; Kuruppu, Darshini; Lanuti, Michael; Goodwin, Jonathan M.; Azoulay, Daniel; Fuchs, Bryan C. // JAMA: Journal of the American Medical Association;1/2/2008, Vol. 299 Issue 1, p53
This article presents the results of a study examining epidermal growth factor (EGF) gene functional polymorphism and the risk of liver cancer in patients with cirrhosis of the liver. Liver cancer is the sixth most common cancer in the world and a leading cause of mortality. It usually appears...